Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Ourobio is a private synthetic biology and biomaterials company developing engineered-microbe fermentation processes that convert industrial and agricultural byproducts into bio-based, biodegradable materials. The company focuses on circular-economy applications rather than therapeutics, with an emphasis on polyhydroxyalkanoate-based plastic resins, pigments, and additives intended to replace petrochemical-derived materials. Ourobio originated from the University of Virginia iGEM project "Transfoam" in 2019 and was spun out in March 2020. Its platform is designed to co-produce complementary biomaterials in a single fermentation process, including initial work using dairy byproducts such as whey as feedstock. The company appears to be an early-stage private startup working with manufacturers and brands on sustainable materials and packaging applications.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Ourobio.